Suppr超能文献

胰腺癌选择性淋巴结照射联合同步整合加量立体定向体部放疗:计划可行性分析及基于几何因素的剂量体积直方图预测模型

Elective nodal irradiation with simultaneous integrated boost stereotactic body radiotherapy for pancreatic cancer: Analyses of planning feasibility and geometrically driven DVH prediction model.

作者信息

Nakamura Akira, Prichard Hugh A, Wo Jennifer Y, Wolfgang John A, Hong Theodore S

机构信息

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

出版信息

J Appl Clin Med Phys. 2019 Feb;20(2):71-83. doi: 10.1002/acm2.12528. Epub 2019 Jan 13.

Abstract

PURPOSE

We evaluate the feasibility of the elective nodal irradiation strategy in stereotactic body radiotherapy (SBRT) for pancreatic cancer.

METHODS

Three simultaneous integrated boost (SIB)-SBRT plans (Boost1, Boost2, and Boost3) were retrospectively generated for each of 20 different patients. Boost1 delivered 33 and 25 Gy to PTV1 and PTV2, respectively. Boost2 delivered 40, 33, and 25 Gy to boostCTV, PTV1, and PTV2, respectively. Boost3 delivered 33 and 25 Gy to PTV1 and PTV3, respectively. PTV1 covered the initial standard SBRT plan (InitPlan) gross tumor volume (GTV). PTV2 covered CTVgeom which was created by a 10-mm expansion (15 mm posterior) of GTV. PTV3 covered CTVprop which included elective nodal regions. The boostCTV included GTV as well as involved vasculature. The planning feasibility in each scenario and dose-volume histograms (DVHs) were analyzed and compared with the InitPlan (delivered 33 Gy only to PTV1) by paired t-test. Next, a novel DVH prediction model was developed and its performance was evaluated according to the prediction accuracy (AC) of planning violations. Then, the model was used to simulate the impacts of GTV-to-organs at risk (OAR) distance and gastrointestinal (GI) OAR volume variations on planning feasibility.

RESULTS

Significant dose increases were observed in GI-OARs in SIB-SBRT plans when compared with InitPlan. All dose constraints were met in 63% of cases in InitPlan, Boost1, and Boost2, whereas Boost3 developed DVH violations in all cases. Utilizing previous patient anatomy, the novel DVH prediction model achieved a high AC in the prediction of violations for GI-OARs; the positive predictive value, negative predictive value, and AC were 66%, 90%, and 84%, respectively. Experiments with the model demonstrated that the larger proximity volume of GI-OAR at the shorter distance substantially impacted on planning violations.

CONCLUSIONS

SIB-SBRT plan with geometrically defined prophylactic areas can be dosimetrically feasible, but including all nodal areas with 25 Gy in five fractions appears to be unrealistic.

摘要

目的

我们评估在胰腺癌立体定向体部放疗(SBRT)中选择性淋巴结照射策略的可行性。

方法

对20例不同患者分别回顾性生成三个同步整合加量(SIB)-SBRT计划(Boost1、Boost2和Boost3)。Boost1分别向计划靶体积1(PTV1)和计划靶体积2(PTV2)给予33 Gy和25 Gy剂量。Boost2分别向增强临床靶体积(boostCTV)、PTV1和PTV2给予40 Gy、33 Gy和25 Gy剂量。Boost3分别向PTV1和计划靶体积3(PTV3)给予33 Gy和25 Gy剂量。PTV1覆盖初始标准SBRT计划(InitPlan)的大体肿瘤体积(GTV)。PTV2覆盖由GTV向外扩展10 mm(后部15 mm)形成的几何临床靶体积(CTVgeom)。PTV3覆盖包含选择性淋巴结区域的临床靶体积(CTVprop)。boostCTV包括GTV以及受累血管。分析每种方案的计划可行性和剂量体积直方图(DVH),并通过配对t检验与InitPlan(仅向PTV1给予33 Gy剂量)进行比较。接下来,开发了一种新的DVH预测模型,并根据计划违规的预测准确性(AC)评估其性能。然后,使用该模型模拟GTV与危及器官(OAR)的距离以及胃肠道(GI)OAR体积变化对计划可行性的影响。

结果

与InitPlan相比,SIB-SBRT计划中GI-OAR的剂量显著增加。InitPlan、Boost1和Boost2中63%的病例满足所有剂量限制,而Boost3在所有病例中均出现DVH违规。利用既往患者解剖结构,新的DVH预测模型在预测GI-OAR违规方面具有较高的AC;阳性预测值、阴性预测值和AC分别为66%、90%和84%。该模型的实验表明,在较短距离处较大的GI-OAR邻近体积对计划违规有显著影响。

结论

具有几何定义的预防区域的SIB-SBRT计划在剂量学上可能是可行的,但在五分次中给予所有淋巴结区域25 Gy剂量似乎不现实。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75bf/6370996/e8a15a59777b/ACM2-20-71-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验